Mizuho analyst Ann Hynes raised the firm’s price target on Charles River (CRL) to $215 from $200 and keeps a Neutral rating on the shares. The firm updated targets in the healthcare facilities and managed care group as part of a Q4 preview. Mizuho’s physician survey indicated healthcare utilization growth trends decelerated sequentially despite easier year-over-year comps, which could indicate trend is peaking, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Orderly Leadership Transition and Governance Enhancements Support Continued Buy Rating on Charles River Labs
- Charles River Laboratories: Overdone CEO-Transition Selloff Creates Attractive Entry Point Amid Improving Fundamentals
- Charles River CEO James Foster to retire, Birgit Girshick to succeed
- Charles River price target raised to $200 from $174 at Mizuho
- Charles River price target raised to $190 from $165 at JPMorgan